- Conditions
- Breast Cancer, Lymphoma, Pain
- Interventions
- Pregabalin, Placebo
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 816
matching trials from the live ClinicalTrials.gov search.
- Conditions
- CLL, Chronic Lymphocytic Leukemia
- Interventions
- Tacabrutideg, Bendamustine, Idelalisib, Rituximab, Venetoclax
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 29
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • San Diego, California + 25 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Interventions
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- GERD
- Interventions
- Nissen fundoplication, baclofen, Desipramine
- Device · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Zanubrutinib, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Boston, Massachusetts • Dallas, Texas
- Conditions
- Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
- Interventions
- Lyrica 300 mg, Placebo
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
- Interventions
- Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypertriglyceridemia With the Metabolic Syndrome
- Interventions
- Fenofibrate (drug)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fibromyalgia
- Interventions
- Gabapentin ER
- Drug
- Lead sponsor
- The Center for Clinical Research, Winston-Salem, NC
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Narcolepsy With Cataplexy
- Interventions
- JZP-258, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 12
- States / cities
- Orange, California • Stanford, California • Boulder, Colorado + 9 more
- Conditions
- Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Bendamustine hydrochloride, Rituximab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 39 more
- Conditions
- Diabetic Nephropathies
- Interventions
- Fenofibrate, Placebo
- Drug · Other
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Acute Pain
- Interventions
- Gabapentin
- Drug
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Restless Legs Syndrome
- Interventions
- Horizant
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Breast Cancer
- Interventions
- bendamustine, erlotinib, Maintenance erlotinib
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Amyloid-beta
- Interventions
- Sodium Oxybate, Sleep deprivation
- Drug · Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Fibromyalgia
- Interventions
- pregabalin, placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 30
- States / cities
- Orange, California • Santa Ana, California • Ocala, Florida + 27 more
- Conditions
- Neuropathy; Radicular, Lumbar, Lumbosacral, Failed Back Surgery Syndrome, Spinal Stenosis, Herniated Disc
- Interventions
- Pregabalin, Sugar Pill
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
- Interventions
- Cal-Mag Butyrate, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Long Beach, California • Miami, Florida • Salt Lake City, Utah
- Conditions
- Alcohol Withdrawal Delirium
- Interventions
- Baclofen, Placebo, Lorazepam
- Drug
- Lead sponsor
- Essentia Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Duluth, Minnesota
- Conditions
- Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- Bendamustine, Rituximab, Lenalidomide
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more